ROIVANT SCIENCES LTD. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ROIVANT SCIENCES LTD. (ROIV) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $83.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- ROIVANT SCIENCES LTD. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $83.34M, a 1.42% increase year-over-year.
- ROIVANT SCIENCES LTD. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $105.00M, a 25.47% increase year-over-year.
- ROIVANT SCIENCES LTD. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $81.82M, a 14.09% increase year-over-year.
- ROIVANT SCIENCES LTD. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $82.18M, a 63.57% increase year-over-year.
- ROIVANT SCIENCES LTD. apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $346.17M, a 19.73% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $289.12M, a 44.60% increase from fiscal 2024.
- ROIVANT SCIENCES LTD. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $199.95M.
- ROIVANT SCIENCES LTD. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $564.96M, a 564.98% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $83.34M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $346.17M 10-K · filed 2026-05-20 | |||
| 2025-12-31 | $105.00M 10-Q · filed 2026-02-06 | $186.82M derived: sum of 2 quarters · filed 2026-02-06 | $269.00M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-09-30 | $81.82M 10-Q · filed 2026-02-06 | $164.00M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $82.18M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $289.12M 10-K · filed 2026-05-20 | |||
| 2024-12-31 | $83.68M 10-Q · filed 2026-02-06 | $155.40M derived: sum of 2 quarters · filed 2026-02-06 | $205.64M derived: sum of 3 quarters · filed 2026-02-06 | |
| 2024-09-30 | $71.72M 10-Q · filed 2026-02-06 | $121.95M derived: sum of 2 quarters · filed 2026-02-06 | ||
| 2024-06-30 | $50.24M 10-Q · filed 2026-02-06 | |||
| 2024-03-31 | $199.95M 10-K · filed 2026-05-20 | |||
| 2022-06-30 | $72.79M 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $564.96M 10-K · filed 2022-06-28 | |||
| 2021-12-31 | $71.22M 10-Q · filed 2022-02-14 | $468.53M derived: sum of 2 quarters · filed 2022-02-14 | $487.80M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-09-30 | $397.31M 10-Q · filed 2022-02-14 | $416.58M derived: sum of 2 quarters · filed 2022-08-15 | ||
| 2021-06-30 | $19.27M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $84.96M 10-K · filed 2022-06-28 | |||
| 2020-12-31 | $17.32M 10-Q · filed 2022-02-14 | $31.24M derived: sum of 2 quarters · filed 2022-02-14 | $45.52M derived: sum of 3 quarters · filed 2022-02-14 | |
| 2020-09-30 | $13.91M 10-Q · filed 2022-02-14 | $28.19M derived: sum of 2 quarters · filed 2022-02-14 | ||
| 2020-06-30 | $14.28M 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |